Titre:
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Auteur:Baselga, José; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horváth, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard; Piccart-Gebhart, Martine; NeoALTTO Study Team,
Informations sur la publication:Lancet, 379, 9816, page (633-640)
Statut de publication:Publié, 2012-02
Sujet CREF:Cancérologie
MeSH keywords:Administration, Oral
Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Breast Neoplasms -- chemistry -- drug therapy -- pathology -- surgery
Chemotherapy, Adjuvant
Diarrhea -- chemically induced
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Liver -- drug effects -- metabolism
Middle Aged
Neoadjuvant Therapy -- methods
Paclitaxel -- administration & dosage -- adverse effects
Quinazolines -- administration & dosage -- adverse effects
Receptor, erbB-2 -- analysis -- antagonists & inhibitors
Treatment Outcome
Tumor Markers, Biological -- analysis -- antagonists & inhibitors
Note générale:Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: cp.j
Langue:Anglais
Identificateurs:urn:issn:0140-6736
info:doi/10.1016/S0140-6736(11)61847-3
info:pii/S0140-6736(11)61847-3
info:scp/84857236823
info:pmid/22257673